June 23, 2010 ·
Leave a comment
A recent PharmaTimes article highlighted the efforts of the largest public/private partnership in the pharmaceutical industry, Europe’s Innovative Medicines Initiative (IMI). The IMI, jointly funded for 2 billion euros by the European Commission and the industry group, the European Federation of Pharmaceutical Industries and Associations (EFPIA), seeks to address the development and delivery issues for critical new medicines that may be too large for an individual institution or company to tackle alone.
According to PharmaTimes, the IMI focuses on “unmet needs common to the pharmaceutical industry and patients – the key concepts being pre-competitive research, open innovation and patient-tailored therapies.” Now in its third year accepting proposals, the initiative will target a number of new developments in pharmaceuticals and patient education, including the development of personalized medicine approaches for the treatment of diabetes and a variety of training programs for creating “informed patients.”
Ongoing projects like the Innovative Medicines Initiative and Italy’s Drug Development and Discovery Unit (see our previous post about the D3 here) are opening up greater opportunities for the pharmaceutical industry to pool its resources and work with the medical community for better public health.
April 13, 2010 ·
A report in yesterday’s Pharma Letter illustrates how critical partnerships between the pharmaceutical industry and academia can be beneficial for patients, medical professionals and the pharmaceutical industry alike. The Italian Institute of Technology’s Drug Discovery and Development Unit (D3) “brings together scientists with experience in industry and academia to discover new drugs in pain, inflammation and dementia.” Having already received considerable funding from the Italian government, D3 is interested in partnering with external collaborators to further projects.
Through its in-depth key opinion leader (KOL) identification and profiling, Thought Leader Select sees how many similar partnerships around the globe are successful in creating innovative therapies and furthering scientific work. We look forward to the advancements that D3 is sure to bring. As partnerships between the industry and leading academic centers of excellence continue to form, we expect today’s breakthrough compounds to become tomorrow’s key medicines for global public health much more quickly.
Institutes like the D3 in Italy will illustrate, on an even greater level, the synergies that inevitably develop when the pharmaceutical industry teams up with the right key opinion leaders for clinical investigation, advisory boards, editorial boards, and other key areas of deployment.
Read the full article here.